RNAZ
Transcode Therapeutics
$5.45
−$0.48 (−8.09%)Jul 27, 2026
Key metrics
The numbers that frame RNAZ today
- Market cap
- $5.18M
- P/E (TTM)
- -0.1
- EV / FCF
- 0.4
- ROIC
- 12,304.9%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $3.82
- 52wk High
- $20.99
Growth
Revenue and earnings trend for RNAZ
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about RNAZ
Is Transcode Therapeutics a good buy?
No. Transcode Therapeutics has poor quality and poor momentum. Both signals point to a weaker setup. Growth looks weak. That could put pressure on the long-term business case.
What is the market capitalization of RNAZ?
Transcode Therapeutics's market capitalization is $5.18M.
What is the P/E ratio for RNAZ stock?
Transcode Therapeutics's current P/E ratio is -0.1.
What is the 52-week high for RNAZ stock?
The 52-week high for Transcode Therapeutics is $20.99. The current close of $5.45 is 74% below that high.
What is the 52-week low for RNAZ stock?
The 52-week low for Transcode Therapeutics is $3.82. The current close of $5.45 is 42.7% above that low.
Does RNAZ stock pay dividends?
Transcode Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for RNAZ?
Transcode Therapeutics's Debt / Equity ratio is 0.